ADMA · Healthcare
ADMA BIOLOGICS INC
Smart-money confidence
· 1 of 3 sources firing
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
52
Congress
0
Insiders
50
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$2.0B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About ADMA BIOLOGICS INC
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure…
Who's behind the signal
Every informed buyer we can see on ADMA, across all three feeds.
Hedge funds · 9
Duquesne Family Office (Druckenmiller)
New position
Bridgewater Associates (Dalio)
Increased +209%
Tudor Investment (Paul Tudor Jones)
Increased +21%
D.E. Shaw & Co
Increased +68%
Millennium Management (Englander)
Increased +135%
Gotham Asset Mgmt (Greenblatt)
Increased +24%
+3 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ADMA BIOLOGICS INC isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
1
New positions
6
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.6×
% of portfolio
0.1%
Position change
NEW
0.1% of Duquesne Family Office's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
+209%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
+21%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+68%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+135%
0.0% of Millennium Management's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+24%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+11%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−28%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−70%
0.0% of Point72's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ADMA BIOLOGICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ADMA BIOLOGICS INC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime